Ikarian Capital’s Gyre Therapeutics GYRE Stock Holding History

Ikarian Capital’s Portfolio GYRE Stock Details GYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-63,550	Closed	-$314K	–	166
2022 Q1	$314K	Buy	63,550 +2,971	+5%	+$14.7K	0.04%	155
2021 Q4	$416K	Hold	60,579	–	–	0.06%	136
2021 Q3	$1.87M	Sell	60,579 -16,914	-22%	-$557K	0.13%	129
2021 Q2	$2.52M	Hold	77,493	–	–	0.2%	117
2021 Q1	$2.93M	Buy	+77,493	New	+$3.54M	0.1%	174

Other funds holding GYRE

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

Ikarian Capital's GYRE Position: Q2 2022 in Review

Ikarian Capital sold out of Gyre Therapeutics (GYRE) in Q2 2022, closing a stake of 63,550 shares — an estimated $314K sold.

Ikarian Capital first reported a position in GYRE in Q1 2021 and held it in 5 quarters. The position peaked at $2.93M in Q1 2021. 41 funds tracked by Wall St. Rank hold GYRE as of Q2 2022.

Ikarian Capital reported no remaining Gyre Therapeutics position as of Q2 2022 after selling out during the quarter.
Ikarian Capital sold 63,550 Gyre Therapeutics shares in Q2 2022, an estimated $314K.
Ikarian Capital first reported a position in Gyre Therapeutics in Q1 2021 and held it in 5 quarters.
Ikarian Capital's Gyre Therapeutics position peaked at $2.93M in Q1 2021.
41 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q2 2022.

Based on Ikarian Capital's 13F filing for Q2 2022, filed 12 Aug 2022.